KR101466931B1 - Sdf-1 결합형 b형 핵산분자 - Google Patents

Sdf-1 결합형 b형 핵산분자

Info

Publication number
KR101466931B1
KR101466931B1 KR1020097000923A KR20097000923A KR101466931B1 KR 101466931 B1 KR101466931 B1 KR 101466931B1 KR 1020097000923 A KR1020097000923 A KR 1020097000923A KR 20097000923 A KR20097000923 A KR 20097000923A KR 101466931 B1 KR101466931 B1 KR 101466931B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
sdf
rna
acid molecule
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097000923A
Other languages
English (en)
Korean (ko)
Other versions
KR20090039717A (ko
Inventor
웨르너르 퍼르쉬케이
플로리안 야로슈
디르크 율베르그
스벤 클루스만
클라우스 부크너르
크리스티안 매쉬
니꼴 딘세
Original Assignee
녹손 파르마 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 녹손 파르마 아게 filed Critical 녹손 파르마 아게
Publication of KR20090039717A publication Critical patent/KR20090039717A/ko
Application granted granted Critical
Publication of KR101466931B1 publication Critical patent/KR101466931B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
KR1020097000923A 2006-07-18 2007-07-18 Sdf-1 결합형 b형 핵산분자 Active KR101466931B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06014957.2 2006-07-18
EP06014957 2006-07-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137020754A Division KR101561652B1 (ko) 2006-07-18 2007-07-18 Sdf-1 결합형 c형 핵산분자

Publications (2)

Publication Number Publication Date
KR20090039717A KR20090039717A (ko) 2009-04-22
KR101466931B1 true KR101466931B1 (ko) 2014-12-02

Family

ID=38947372

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137020754A Active KR101561652B1 (ko) 2006-07-18 2007-07-18 Sdf-1 결합형 c형 핵산분자
KR1020097000923A Active KR101466931B1 (ko) 2006-07-18 2007-07-18 Sdf-1 결합형 b형 핵산분자

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020137020754A Active KR101561652B1 (ko) 2006-07-18 2007-07-18 Sdf-1 결합형 c형 핵산분자

Country Status (16)

Country Link
US (5) US8314223B2 (enExample)
EP (1) EP2041282B1 (enExample)
JP (1) JP5380287B2 (enExample)
KR (2) KR101561652B1 (enExample)
CN (2) CN101506364B (enExample)
AR (1) AR061929A1 (enExample)
AU (1) AU2007276435C1 (enExample)
BR (1) BRPI0714844B8 (enExample)
CA (1) CA2658267C (enExample)
DK (1) DK2041282T3 (enExample)
ES (1) ES2663404T3 (enExample)
MX (1) MX2009000656A (enExample)
PL (1) PL2041282T3 (enExample)
PT (1) PT2041282T (enExample)
RU (1) RU2590709C2 (enExample)
WO (1) WO2008009437A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2590709C2 (ru) 2006-07-18 2016-07-10 Ноксон Фарма Аг Sdf-1-связывающие нуклеиновые кислоты
PT2190991T (pt) * 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
JP5463621B2 (ja) 2008-02-27 2014-04-09 ソニー株式会社 標的物質の定量方法
JP5559159B2 (ja) * 2008-06-11 2014-07-23 バイオニュークレオン ソチエタ・レスポンサビリタ・リミタータ 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
WO2012025251A1 (en) * 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
US20130310442A1 (en) * 2010-09-09 2013-11-21 Noxxon Pharma Ag SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
EP2633053A1 (en) * 2010-10-29 2013-09-04 Noxxon Pharma AG Use of hepcidin binding nucleic acids for depletion of hepcidin from the body
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
AU2015366512A1 (en) * 2014-12-17 2017-07-13 Cancer Research Technology Ltd. Anti-CXCL12 antibody molecules and their uses
WO2017178119A1 (en) * 2016-04-15 2017-10-19 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
US11221270B2 (en) * 2018-02-27 2022-01-11 Kevan M Evans Method and apparatus for detecting slow leaks
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072273A1 (en) * 1998-03-24 2001-01-31 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
WO2002101350A2 (en) * 2001-06-07 2002-12-19 Chemocentryx Cell migration assay
WO2006032143A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
AU1435492A (en) * 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6670149B1 (en) * 1999-03-01 2003-12-30 Millennium Pharmaceuticals, Inc. TWIK-5 potassium channel nucleic acids and uses therefor
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
EP1133988A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
GB0225833D0 (en) 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
DE502005009920D1 (de) * 2004-11-29 2010-08-26 Noxxon Pharma Ag Vasopressin bindende l-nukleinsäure
EP2397148A3 (en) 2006-02-02 2012-04-25 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
RU2590709C2 (ru) 2006-07-18 2016-07-10 Ноксон Фарма Аг Sdf-1-связывающие нуклеиновые кислоты
AR063086A1 (es) 2006-10-02 2008-12-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
AU2007325029B2 (en) 2006-11-30 2013-09-12 The Regents Of The University Of California Methods for treating and diagnosing fibrotic and fibroproliferative diseases
PT2190991T (pt) 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
US20090274687A1 (en) 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072273A1 (en) * 1998-03-24 2001-01-31 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
WO2002101350A2 (en) * 2001-06-07 2002-12-19 Chemocentryx Cell migration assay
WO2006032143A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Journal of Neuroscience Vol.23(4):1360-1371 (2003. 02. 15.) *

Also Published As

Publication number Publication date
CN103555725A (zh) 2014-02-05
PL2041282T3 (pl) 2018-07-31
BRPI0714844A2 (pt) 2013-11-26
AU2007276435A1 (en) 2008-01-24
JP5380287B2 (ja) 2014-01-08
ES2663404T3 (es) 2018-04-12
RU2009105494A (ru) 2010-08-27
CN101506364A (zh) 2009-08-12
EP2041282B1 (en) 2018-01-03
KR20090039717A (ko) 2009-04-22
MX2009000656A (es) 2009-03-25
DK2041282T3 (en) 2018-04-16
RU2590709C2 (ru) 2016-07-10
KR20130090428A (ko) 2013-08-13
US20110112172A1 (en) 2011-05-12
AR061929A1 (es) 2008-10-01
JP2009543567A (ja) 2009-12-10
CA2658267A1 (en) 2008-01-24
US8314223B2 (en) 2012-11-20
EP2041282A2 (en) 2009-04-01
US9035038B2 (en) 2015-05-19
BRPI0714844B1 (pt) 2019-10-01
AU2007276435C1 (en) 2013-06-13
US20180163207A1 (en) 2018-06-14
CN103555725B (zh) 2017-05-24
CA2658267C (en) 2021-03-30
US20130041019A1 (en) 2013-02-14
WO2008009437A3 (en) 2008-03-27
AU2007276435B2 (en) 2013-01-24
US20150232853A1 (en) 2015-08-20
US9822369B2 (en) 2017-11-21
HK1131184A1 (en) 2010-01-15
BRPI0714844B8 (pt) 2023-04-18
WO2008009437A2 (en) 2008-01-24
US20210139909A1 (en) 2021-05-13
PT2041282T (pt) 2018-03-13
KR101561652B1 (ko) 2015-10-20
CN101506364B (zh) 2013-10-30

Similar Documents

Publication Publication Date Title
KR101466931B1 (ko) Sdf-1 결합형 b형 핵산분자
KR101589442B1 (ko) 에스디에프-1 결합형 핵산 및 이의 용도
KR101572893B1 (ko) Mcp-1 결합형 3형 핵산
HK1131184B (en) Sdf-i binding nucleic acids
AU2013200034A1 (en) Sdf-i binding nucleic acids
HK1144956B (en) Sdf-1 binding nucleic acids and the use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110328

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130206

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130806

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131029

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140828

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141124

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141125

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20171025

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20171025

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20181108

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20181108

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20191029

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20191029

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20201028

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20221026

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20231025

Start annual number: 10

End annual number: 10